United States

NIH funds precision medicine research with a focus on health disparities

Friday, July 29, 2016

The National Institute on Minority Health and Health Disparities (NIMHD), part of the NIH, has committed approximately $31 million over five years, pending available funding, to launch a new program for Transdisciplinary Collaborative Centers (TCCs) for health disparities research exploring the potential for precision medicine to promote health equity and advance the science of minority health and health disparities.

[Read More]

Alere hit with subpoena for Medicare billing practices

Thursday, July 28, 2016

Investors were temporarily shaken after news of a federal investigation into Medicare billing practices. Alere received a U.S. Department of Justice subpoena addressed to Alere Toxicology Services on July 1, 2016. The subpoena seeks records related to Medicare, Medicaid and Tricare billings dating back to 2010 for patient samples tested at the company’s Austin, Texas pain management laboratory.

[Read More]

Embera wins $11M NIDA grant for cocaine addiction treatment EMB-001

Wednesday, July 27, 2016

Embera NeuroTherapeutics, a specialty pharmaceutical company developing novel treatments for cocaine, nicotine, and other addictions, has received an $11.1 million, three-year grant from the National Institute on Drug Abuse (NIDA), part of the NIH. The grant will support continued clinical development of EMB-001 for the treatment of cocaine addiction, which is clinically termed “cocaine use disorder.”

[Read More]

FDA grants QIDP, Fast Track Designations to MCB3837

Tuesday, July 26, 2016

Morphochem, a clinical-stage pharmaceutical company, has announced that the FDA has designated Morphochem’s intravenous (IV) antibacterial product candidate MCB3837 as a Qualified Infectious Disease Product (QIDP) for the treatment of Clostridium difficile infection (CDI). At the same time, the FDA has granted Fast Track designation to the compound’s development program for the treatment of CDI. MCB3837 is the IV prodrug of MCB3681, an antibacterial targeted at the treatment of CDI, which is a serious and potentially fatal disease regarded as an urgent healthcare threat.

[Read More]